Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer
| Autor: | Beth Erickson, Douglas B. Evans, Murad Aburajab, Susan Tsai, Parag Tolat, Elliot A. Asare |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
medicine.medical_specialty Cost effectiveness business.industry medicine.medical_treatment General Medicine Multimodality Therapy medicine.disease 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine Pancreatic cancer Pancreatectomy medicine Adjuvant therapy 030211 gastroenterology & hepatology Surgery business Value (mathematics) Adjuvant Neoadjuvant therapy |
| Zdroj: | Journal of Surgical Oncology. 114:291-295 |
| ISSN: | 0022-4790 |
| DOI: | 10.1002/jso.24316 |
| Popis: | Treatment sequencing for resectable pancreatic cancer remains controversial and there is lack of level one evidence comparing neoadjuvant versus adjuvant strategies. However, a comparison of the cost-effectiveness analysis of the treatment strategies may help to better define the healthcare value of each approach. This review will highlight the rationale for multimodality therapy in the treatment of pancreatic cancer, discuss the advantages and disadvantages of adjuvant therapy, and conceptualize the cost-effectiveness of a neoadjuvant approach with regard to healthcare value. J. Surg. Oncol. 2016;114:291-295. © 2016 Wiley Periodicals, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text